Opthea Ltd ADR (OPT)

$3.41 +0.23 (7.23%)
Market Cap 524.84M
Revenue (ttm) 120,000.00
Net Income (ttm) -220.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -183,533.34%
Debt to Equity Ratio -1.32
Volume 3,000
Avg Vol 38,738
Day's Range N/A - N/A
Shares Out 153.91M
Stochastic %K 33%
Beta 1.12
Analysts Strong Sell
Price Target $12.00

Company Profile

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian T...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
Website: opthea.com
Address:
Level 9, 505 Little Collins Street, Melbourne, Australia
goldrush77
goldrush77 Mar. 3 at 3:22 PM
$OPT 1,000,000 @bid . That is 0.7 % of the total shares
0 · Reply
goldrush77
goldrush77 Mar. 2 at 5:47 PM
$OPT Not a Pinkshit : "As at 31 December 2025....The Company held cash and cash equivalents of $33.2 million."
1 · Reply
goldrush77
goldrush77 Mar. 2 at 5:36 PM
$OPT Reports '25 audited. Relisting ASX on the way...
0 · Reply
goldrush77
goldrush77 Mar. 2 at 5:26 PM
$OPT This is a big one: Net tangible assets per ADR (=8 shares) =0.14 USD new !!! (previous period -1.42USD (correct read: minus!) https://ir.opthea.com/static-files/a874747e-3b6e-4016-882c-471a882eb1b1
0 · Reply
Nhraracer
Nhraracer Jan. 13 at 12:31 AM
$OPTT this is $OPT dummy not $OPTT 2 different tickers but nice try pumper😂🤣
5 · Reply
TwongStocks
TwongStocks Nov. 20 at 1:45 AM
$OPT FINRA's daily list confirms this will trade OTC effective Nov 20. New symbol is $OPTEY https://otce.finra.org/otce/dailyList
0 · Reply
OPTIOBlockchain
OPTIOBlockchain Nov. 16 at 7:56 PM
$INJ.X Good add here! Check out $OPT it is listing at 8:00 am on MEXC
0 · Reply
OPTIOBlockchain
OPTIOBlockchain Nov. 5 at 2:25 PM
$BETA.X Check out news for $OPT
0 · Reply
hagentrader
hagentrader Nov. 5 at 1:05 AM
$OPT Training = revenue with very low expense $$$$
0 · Reply
geegor
geegor Oct. 29 at 10:44 PM
$OPT seeks delisting from Nasdaq, with last trading expected here on or about Nov 19:
1 · Reply
Latest News on OPT
Opthea Provides Corporate Update

Aug 18, 2025, 7:00 PM EDT - 7 months ago

Opthea Provides Corporate Update

Opthea Announces Decision to Discontinue Wet AMD Trials

Mar 31, 2025, 12:01 AM EDT - 1 year ago

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces COAST Phase 3 Trial Topline Results

Mar 24, 2025, 12:01 AM EDT - 1 year ago

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Announces Phase 2b Wet AMD Publication

Mar 3, 2025, 7:00 AM EST - 1 year ago

Opthea Announces Phase 2b Wet AMD Publication

Opthea to Present at Oppenheimer Healthcare Conference

Feb 7, 2025, 7:00 AM EST - 1 year ago

Opthea to Present at Oppenheimer Healthcare Conference

Opthea Wet AMD Data Featured at Macula Society Meeting

Feb 6, 2025, 7:00 AM EST - 1 year ago

Opthea Wet AMD Data Featured at Macula Society Meeting

Opthea to Host Investor Days in New York and Australia

Jan 8, 2025, 7:00 AM EST - 1 year ago

Opthea to Host Investor Days in New York and Australia

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 1 year ago

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Opthea's Wet AMD Program to be Featured at FLORetina 2024

Nov 26, 2024, 7:00 AM EST - 1 year ago

Opthea's Wet AMD Program to be Featured at FLORetina 2024

Opthea Appoints Kathy Connell to Board of Directors

Nov 15, 2024, 7:00 AM EST - 1 year ago

Opthea Appoints Kathy Connell to Board of Directors

Opthea Wet AMD Program to be Presented at Innovate Retina

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Opthea Wet AMD Program to be Presented at Innovate Retina

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

Opthea Announces Executive Leadership Changes and Senior Hires

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Opthea Announces Executive Leadership Changes and Senior Hires

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Opthea Reports Full-Year Financial Results and Business Updates

Aug 30, 2024, 7:30 AM EDT - 1 year ago

Opthea Reports Full-Year Financial Results and Business Updates

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Aug 8, 2024, 8:10 AM EDT - 1 year ago

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Jul 17, 2024, 7:15 AM EDT - 1 year ago

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer

Jul 14, 2024, 9:46 PM EDT - 1 year ago

Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer

Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

Jun 18, 2024, 8:57 PM EDT - 1 year ago

Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

Jun 13, 2024, 7:58 PM EDT - 1 year ago

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

Jun 11, 2024, 9:13 PM EDT - 1 year ago

Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)

Opthea To Present at Clinical Trials at the Summit Meeting

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Opthea To Present at Clinical Trials at the Summit Meeting

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

May 28, 2024, 7:30 AM EDT - 1 year ago

Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

Opthea Announces Upcoming Presentations at the Retina World Congress 2024

May 1, 2024, 7:30 AM EDT - 2 years ago

Opthea Announces Upcoming Presentations at the Retina World Congress 2024

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Apr 25, 2024, 9:00 AM EDT - 2 years ago

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Apr 8, 2024, 6:42 PM EDT - 2 years ago

Opthea Appoints John Han, PharmD, as VP Medical Affairs

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 6:34 PM EDT - 2 years ago

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

Opthea Appoints Sujal Shah to the Board of Directors

Apr 3, 2024, 5:39 PM EDT - 2 years ago

Opthea Appoints Sujal Shah to the Board of Directors

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Mar 19, 2024, 6:00 AM EDT - 2 years ago

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 5:08 PM EST - 2 years ago

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Opthea Reports Half-Year Financial Results and Business Updates

Feb 28, 2024, 5:55 PM EST - 2 years ago

Opthea Reports Half-Year Financial Results and Business Updates

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Feb 19, 2024, 6:25 PM EST - 2 years ago

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Feb 14, 2024, 7:00 AM EST - 2 years ago

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Feb 1, 2024, 6:00 AM EST - 2 years ago

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Dec 27, 2023, 6:00 AM EST - 2 years ago

Opthea to Receive US$35M Commitment and Additional US$50M Funding

Opthea Receives A$8.8 million R&D Tax Incentive

Dec 19, 2023, 6:00 AM EST - 2 years ago

Opthea Receives A$8.8 million R&D Tax Incentive

Opthea to Present at the FLORetina 2023 Congress

Dec 1, 2023, 5:30 AM EST - 2 years ago

Opthea to Present at the FLORetina 2023 Congress

Opthea to Present at the Jefferies 2023 London Healthcare Conference

Nov 9, 2023, 5:30 AM EST - 2 years ago

Opthea to Present at the Jefferies 2023 London Healthcare Conference

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Oct 30, 2023, 5:30 AM EDT - 2 years ago

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Oct 27, 2023, 5:30 AM EDT - 2 years ago

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Opthea to Participate at the 2023 Euretina Congress

Oct 2, 2023, 5:30 AM EDT - 2 years ago

Opthea to Participate at the 2023 Euretina Congress

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 5:30 AM EDT - 2 years ago

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

Aug 28, 2023, 5:30 AM EDT - 2 years ago

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Jul 26, 2023, 6:00 AM EDT - 2 years ago

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Jul 24, 2023, 6:00 AM EDT - 2 years ago

Opthea to Present at the 2023 Ophthalmology Innovation Summit

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Jul 13, 2023, 6:00 AM EDT - 2 years ago

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Jul 10, 2023, 6:00 AM EDT - 2 years ago

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

Jun 8, 2023, 6:00 AM EDT - 2 years ago

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

goldrush77
goldrush77 Mar. 3 at 3:22 PM
$OPT 1,000,000 @bid . That is 0.7 % of the total shares
0 · Reply
goldrush77
goldrush77 Mar. 2 at 5:47 PM
$OPT Not a Pinkshit : "As at 31 December 2025....The Company held cash and cash equivalents of $33.2 million."
1 · Reply
goldrush77
goldrush77 Mar. 2 at 5:36 PM
$OPT Reports '25 audited. Relisting ASX on the way...
0 · Reply
goldrush77
goldrush77 Mar. 2 at 5:26 PM
$OPT This is a big one: Net tangible assets per ADR (=8 shares) =0.14 USD new !!! (previous period -1.42USD (correct read: minus!) https://ir.opthea.com/static-files/a874747e-3b6e-4016-882c-471a882eb1b1
0 · Reply
Nhraracer
Nhraracer Jan. 13 at 12:31 AM
$OPTT this is $OPT dummy not $OPTT 2 different tickers but nice try pumper😂🤣
5 · Reply
TwongStocks
TwongStocks Nov. 20 at 1:45 AM
$OPT FINRA's daily list confirms this will trade OTC effective Nov 20. New symbol is $OPTEY https://otce.finra.org/otce/dailyList
0 · Reply
OPTIOBlockchain
OPTIOBlockchain Nov. 16 at 7:56 PM
$INJ.X Good add here! Check out $OPT it is listing at 8:00 am on MEXC
0 · Reply
OPTIOBlockchain
OPTIOBlockchain Nov. 5 at 2:25 PM
$BETA.X Check out news for $OPT
0 · Reply
hagentrader
hagentrader Nov. 5 at 1:05 AM
$OPT Training = revenue with very low expense $$$$
0 · Reply
geegor
geegor Oct. 29 at 10:44 PM
$OPT seeks delisting from Nasdaq, with last trading expected here on or about Nov 19:
1 · Reply
OPTIOBlockchain
OPTIOBlockchain Oct. 29 at 12:02 AM
$OPT.X Parler Cloud Technologies was just mentioned in SEC Filings yesterday with AMZE. Parler Cloud Technologies will be going the NYSE via IPO late Q1 or early Q2 2026 and is was valued at over 1.5 Billion a few months ago. A very very bright future for $OPT
0 · Reply
TwongStocks
TwongStocks Aug. 20 at 2:05 PM
$OPT Link to corporate presentation of the latest status https://www.sec.gov/Archives/edgar/data/1815620/000095017025110268/opt-ex99_1.htm • After negative topline of COAST & ShORE trials, OPT decided to terminate Sozinibercept wet AMD program after consultation with DFA investors. • OPT settled with DFA investors, with a cash payment of $20M USD and 9.99% equity stake (136.7m shares). The DFA and all liens are terminated. • After settlement, OPT has $20M cash and ~1.4B shares outstanding. No more debt, no liens on any asset. • Trading remains suspended on ASX and NASDAQ. OPT engaging with ASX, I assume NASDAQ will resume trading once trading resumes on ASX. • Remaining board members will pursue strategic transactions
0 · Reply
TwongStocks
TwongStocks Aug. 18 at 11:13 PM
$OPT They have finally issued an update https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-provides-corporate-update-2 • CEO, CFO, and one of the Directors are stepping down. • Board of Directors will conduct a strategic review • They have come to an agreement with the DFA investors. As part of the settlement, the DFA investors will be issued 9.99% of company shares. They will also receive a one-time cash payout of $20M USD. • Trading in ASX remains suspended. I assume NASDAQ will also maintain a halt while trading is suspended on the ASX. • The Company will host a webcast on Tuesday 19 August at 7pm ET/Wednesday 20 August at 9am AEDT.
0 · Reply
tommytoughknuckles
tommytoughknuckles Jun. 27 at 2:19 AM
$OPT how long can they keep this halted for??
1 · Reply
liquidmetal
liquidmetal Jun. 22 at 5:23 PM
$OPT, ethernet at sea. Equip to handle 5g and beyond antena. https://oceanpowertechnologies.com/products/powerbuoys/
0 · Reply
PaytiencePaysGreen
PaytiencePaysGreen Jun. 18 at 11:30 AM
$BTAI POS stock. Prob gonna add to the family and be the same as $SYRS $PTN $OPT . Check these twits out at their board
0 · Reply
geegor
geegor Jun. 2 at 9:41 AM
$OPT Four directors gone from the board today and "...Management plans to hold an investor call to discuss the Phase III trial results and next steps of the Company once active negotiations with the DFA investors have been concluded." https://www.marketindex.com.au/asx/opt/announcements/opthea-provides-corporate-update-3A669187
0 · Reply
TwongStocks
TwongStocks Apr. 10 at 10:33 PM
$OPT Kind of wild. Trading will still remain paused, no timeline for resumption. "In light of these matters, there remains material uncertainty as to Opthea's ability to continue as a going concern. As noted above, discussions with the DFA Investors are ongoing and Opthea cannot be certain as to the outcome of those discussions or when that outcome may become known. " https://www.sec.gov/Archives/edgar/data/1815620/000095017025052661/opt-ex99_1.htm • 65% workforce reduction, expected to be effective May 1. • Remains in active negotiations with its DFA Investors to explore possible options to deliver the best outcome for the Company and its shareholders. • $100M at end of March
0 · Reply
briefingcom
briefingcom Apr. 10 at 12:48 PM
$OPT: Opthea Ltd. announces reduction in force of approximately 65% to preserve cash https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250410063005OPT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
tommytoughknuckles
tommytoughknuckles Apr. 8 at 5:03 AM
$OPT when the hell is this gonna start trading again?
0 · Reply
PaytiencePaysGreen
PaytiencePaysGreen Apr. 1 at 4:38 PM
$OPT outright daylight robbery to retailers. Opt to change name to Apt. Meet at the slaughterhouse...apt,apt,apt,apt..uh huh, uh huh
0 · Reply